Severe Asthma ToolkitSevere Asthma Toolkit
HomeAboutSpecific PopulationsRegistriesContributorsContact
Twitter
  • What is Severe Asthma?
    • Overview
    • Definition
    • Prevalence & Burden
    • Pathophysiology
    • Symptoms
    • Severe Asthma Attacks / Exacerbations / Flare-ups
    • Asthma Phenotypes
  • Diagnosis & Assessment
    • Overview
    • Diagnosis Overview
    • Assessment Overview
    • Lung Function Assessments
    • Questionnaires
    • Allergy Assessments
    • Phenotyping
    • Bronchoscopy
    • Imaging
    • Occupational Asthma
  • Management
    • Overview
    • Asthma Education
      • About Severe Asthma
      • Asthma Pathophysiology
      • Medications Education
      • Self-Monitoring
      • Triggers
      • Review
    • Written Action Plans
    • Adherence
    • Inhaler Technique
    • Physical Activity & Exercise
    • Interdisciplinary Approach & Multidimensional Assessment
    • Referral
  • Medications
    • Overview
    • Relievers
    • Preventers / Controllers
    • Add-on Therapies
    • Monoclonal Antibodies
    • Bronchial Thermoplasty
  • Co-Morbidities
    • Overview
    • Pulmonary & Upper Airways
      • Allergic & Non-Allergic Rhinitis
      • Chronic Rhinosinusitis
      • Dysfunctional Breathing
      • Vocal Cord Dysfunction
      • Chronic Obstructive Pulmonary Disease
      • Bronchiectasis
      • Obstructive Sleep Apnoea
    • Extra-Pulmonary
      • Obesity
      • Anxiety & Depression
      • Gastro-oesophageal Reflux Disease (GORD)
      • Osteoporosis
      • Cardiovascular Disease & Metabolic Disease
  • Living with Severe Asthma
    • Overview
    • Daily Symptom Burden
    • Mental & Emotional Health
    • Intimacy & Relationships
    • Self-Management Support
    • Medication Use & Costs
    • Experience of Care
    • Experience of Asthma Attacks
    • Prognosis
  • Establishing a Clinic
    • Overview
    • Set-up
    • Staffing & Multidisciplinary Team Approach
    • Facilities
    • Delivery Approach
    • Tailored Referrals
    • Evaluation
    • Opportunities for Training & Research
    • Barriers & Hurdles
  • Paediatrics
    • Overview
    • Management in Paediatrics
    • Assessment in Paediatrics
    • Alternative Diagnosis & Co-Morbidities in Paediatrics
    • Psychosocial Issues in Paediatrics
    • Medications in Paediatrics
    • Asthma in the Adolescent Population
  • Resources
    • Overview
    • Clinic Recommendations
    • Infographics
    • Asthma Assessment Resources
    • Systematic & Multidimensional Assessment Resources
      • Airway Components
      • Comorbidity Components
      • Risk Factor Components
    • Translation & Implementation
    • Case Studies
    • Presentations
    • Videos
    • Relevant Links
    • Key References

Relievers

Home Medications Relievers
Reliever

Reliever medications (rapid-onset inhaled beta2 agonists) provide rapid relief from asthma symptoms. All people with asthma should be encouraged to carry their reliever medications at all times. Relievers should be used as-needed for relief of symptoms, and at the lowest dose and frequency required. Regular use of short acting inhaled beta2 agonists should be discouraged. In Australia, most relievers are available from the pharmacy without a prescription. The Australian Asthma Handbook provides information on reliever use.

Reliever medications are bronchodilators, rapidly relaxing the muscle around the airways and improving airflow. A detailed summary of beta2 agonist function is available in (Hall 2009).

High use of relievers can be a risk factor for exacerbations and indicative of poor disease control. When high-doses are needed, at intervals of less than every 4-hours, individuals should be assessed by a doctor. Provided there are additional features to confirm a diagnosis of poor asthma control, the patient will likely require systemic corticosteroids. High use of relievers may also reflect other diagnoses such as anxiety, VCD or dysfunctional breathing, and this will need to managed as appropriate. For more information, see Co-morbidities.

A requirement for reliever medication more than twice per week should prompt a review. This would include patient assessment of the reasons for increased symptoms and increased reliever use, review of adherence and inhaler technique, exclusion of alternative diagnoses, measurement of lung function and possible adjustments to preventer therapy.

Treatment Class Example Medications
Short-acting beta2 agonists (SABA) Salbutamol

Terbutaline

ICS / Rapid-onset long-acting beta2 agonists (LABA) combinations Budesonide/eformoterol fumarate dihydrate

The National Asthma Council Australia has developed a useful Asthma & COPD Medications chart, with images of inhaler devices and available dosages.

Next

Last Updated on February 12, 2019

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

More results...

  • Overview
  • Relievers
  • Preventers / Controllers
  • Add-on Therapies
  • Monoclonal Antibodies
  • Bronchial Thermoplasty
For considerations relevant to the paediatric and adolescent population, please see Medications in Paediatrics

We want to know who accesses the Severe Asthma Toolkit and how it is used. Please complete our survey.

Responses will inform the continued development of the Severe Asthma Toolkit and future translation and implementation activities. Any feedback you provide will be greatly appreciated.

Complete Survey

  • Website Terms of Use
  • Website Survey
© Copyright 2018    CRICOS Provider Number 00109J    The University of Newcastle, Australia